Healthcare / Medical Instruments & SuppliesLSE
$215.50
-2.00 (-0.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $10.7M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$468M
P/E
43.1x
↑EV/EBITDA
1079.4x
↑ROE
3.8%
↑Gross Margin
53.4%
↑Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+22.6%
FCF CAGR
+5.7%
FCF margin
8.7%
FCF / Net income
2.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $228.9M · net income $10.0M · FCF $20.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $228.9M | $228.9M | $177.5M | $126.2M | $124.3M |
| Net Income | $10.0M | $10.0M | $7.1M | $15.9M | $20.4M |
| EBITDA | $44.0M | $44.0M | $29.5M | $32.3M | $35.1M |
| EPS | 0.05 | 0.05 | 0.03 | 0.07 | 0.09 |
| Gross Margin | 53.4% | 53.4% | 52.2% | 55.6% | 59.0% |
| Operating Margin | 12.4% | 12.4% | 12.5% | 15.0% | 20.0% |
| Net Margin | 4.3% | 4.3% | 4.0% | 12.6% | 16.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.36 | 0.04 | 0.04 |
| Current Ratio | 2.79 | 2.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $20.0M | $20.0M | $10.7M | $2.5M | $16.9M |
| Returns | |||||
| ROE | 3.8% | 3.8% | 2.9% | 6.5% | 8.6% |
| Valuation | |||||
| P/E | 43.10 | 43.10 | 5913.85 | 2779.31 | 2822.58 |
| EV/EBITDA | 1079.40 | 1079.40 | 1423.32 | 1365.20 | 1638.42 |
| P/B | 183.21 | 183.21 | 174.26 | 180.94 | 243.48 |
| Growth & Yield | |||||
| Revenue Growth | 29.0% | 29.0% | 40.7% | 1.5% | — |
| EPS Growth | 39.1% | 39.1% | -55.2% | -22.0% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
650.7%
EPS terminal req.
$19.12
Spread vs growth
-611.6%
5Y implied EPS CAGR
248.2%
EPS terminal req.
$23.14
Spread vs growth
-209.1%
10Y implied EPS CAGR
95.7%
EPS terminal req.
$37.26
Spread vs growth
-56.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.9%
Start / end P/E
6461.5x → 4767.7x
EPS bridge
0.03 → 0.05
Residual
-10.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.